Curacyte in shock Phase III failure
This article was originally published in Scrip
Executive Summary
Curacyte has terminated a Phase III trial of its shock treatment PHP/Hemoximer on the recommendation of the data monitoring board. It follows a review of data from 300 patients, or 66% of the study population, which showed that the addition of the drug led to an increased number of deaths compared with the placebo arm. This was the third interim analysis on safety and mortality of the trial.